Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:KMDA NASDAQ:NGNE NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$7.82+1.4%$4.42$1.99▼$8.26$295.38M-0.22192,821 shs324,164 shsKMDAKamada$6.87+0.3%$6.93$5.28▼$9.15$395.06M0.8479,939 shs53,283 shsNGNENeurogene$29.89+4.1%$22.22$6.88▼$74.49$426.59M1.58235,784 shs107,551 shsSAGESage Therapeutics$8.68$8.88$4.62▼$11.44$543.54M0.263.63 million shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux0.00%+36.71%+85.75%+134.13%+215.32%KMDAKamada0.00%+1.78%+2.69%-11.01%+28.65%NGNENeurogene0.00%+2.96%+71.68%+31.56%-38.43%SAGESage Therapeutics0.00%0.00%0.00%-1.36%+13.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$7.82+1.4%$4.42$1.99▼$8.26$295.38M-0.22192,821 shs324,164 shsKMDAKamada$6.87+0.3%$6.93$5.28▼$9.15$395.06M0.8479,939 shs53,283 shsNGNENeurogene$29.89+4.1%$22.22$6.88▼$74.49$426.59M1.58235,784 shs107,551 shsSAGESage Therapeutics$8.68$8.88$4.62▼$11.44$543.54M0.263.63 million shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux0.00%+36.71%+85.75%+134.13%+215.32%KMDAKamada0.00%+1.78%+2.69%-11.01%+28.65%NGNENeurogene0.00%+2.96%+71.68%+31.56%-38.43%SAGESage Therapeutics0.00%0.00%0.00%-1.36%+13.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 2.60Moderate Buy$18.83140.84% UpsideKMDAKamada 2.75Moderate Buy$13.0089.23% UpsideNGNENeurogene 2.56Moderate Buy$46.1754.46% UpsideSAGESage Therapeutics 1.92Reduce$7.85-9.56% DownsideCurrent Analyst Ratings BreakdownLatest GNLX, KMDA, NGNE, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/25/2025KMDAKamadaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/25/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025GNLXGeneluxMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$20.0010/21/2025GNLXGeneluxLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.0010/21/2025GNLXGeneluxLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.0010/9/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.0010/8/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025KMDAKamadaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$45.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K29,536.14N/AN/A$0.76 per share10.29KMDAKamada$160.95M2.45$0.49 per share13.97$4.51 per share1.52NGNENeurogene$930K458.63N/AN/A$20.89 per share1.43SAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)KMDAKamada$14.46M$0.3420.2121.470.7011.22%7.41%5.18%11/12/2025 (Estimated)NGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)SAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%11/4/2025 (Estimated)Latest GNLX, KMDA, NGNE, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/17/2025Q3 2025NGNENeurogene-$1.26N/AN/AN/AN/AN/A11/13/2025N/AGNLXGenelux-$0.23N/AN/AN/AN/AN/A11/12/2025Q3 2025KMDAKamada$0.10N/AN/AN/AN/AN/A8/13/2025Q2 2025KMDAKamada$0.09$0.13+$0.04$0.13$158.59 million$44.75 million8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A7/30/2025Q2 2025SAGESage Therapeutics-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.184.18KMDAKamadaN/A4.002.21NGNENeurogeneN/A18.0718.07SAGESage TherapeuticsN/A9.169.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%KMDAKamada20.38%NGNENeurogene52.37%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipGNLXGenelux8.80%KMDAKamada36.10%NGNENeurogene11.64%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableKMDAKamada36057.51 million36.75 millionOptionableNGNENeurogene9014.27 million12.61 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableGNLX, KMDA, NGNE, and SAGE HeadlinesRecent News About These CompaniesBiogen’s Zurzuvae approved as first postpartum depression drug in EuropeSeptember 18, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric PortfolioSeptember 2, 2025 | finance.yahoo.comUK Regulator Approves Biogen’s Drug For Treating Postnatal DepressionAugust 27, 2025 | msn.comReunion’s psychedelic drug headed to late-stage testingAugust 18, 2025 | yahoo.comWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring TodayAugust 6, 2025 | finance.yahoo.comSage (SAGE) Q2 Revenue Jumps 264%August 1, 2025 | aol.comASupernus strengthens neuropsychiatric portfolio with Sage TherapeuticsAugust 1, 2025 | finance.yahoo.comSage Therapeutics Announces Second Quarter 2025 Financial ResultsJuly 31, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30, 2025 | zacks.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9, 2025 | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9, 2025 | msn.comRx Rundown: AbbVie, Healthline, Beckley Psytech and moreJuly 3, 2025 | mmm-online.comMSage’s Search for Lifeline Ran Into Defiant Biogen CEOJuly 3, 2025 | biospace.comBM&A ramped up in June, with blueBird, Sage and Snyk tie-upsJuly 2, 2025 | bizjournals.comBoston-area pharma company to lay off entire 300-person staff after saleJuly 1, 2025 | msn.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)July 1, 2025 | globenewswire.comWhat Makes Sage Therapeutics (SAGE) a New Buy StockJuly 1, 2025 | zacks.comSage Therapeutics cuts most of its workforce following acquisitionJuly 1, 2025 | statnews.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNLX, KMDA, NGNE, and SAGE Company DescriptionsGenelux NASDAQ:GNLX$7.82 +0.11 (+1.43%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.88 +0.06 (+0.72%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Kamada NASDAQ:KMDA$6.87 +0.02 (+0.29%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$6.85 -0.02 (-0.35%) As of 10/24/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Neurogene NASDAQ:NGNE$29.89 +1.18 (+4.11%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$29.87 -0.02 (-0.07%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Sage Therapeutics NASDAQ:SAGESage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
